Drug Trial Radar · NCT07731802
Finasteride and Cutibacterium
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Mar 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
High levels of Testosterone causes high amounts of skin bacteria (Cutibacterium Acnes) which can go into the skin during a shoulder replacement surgery and cause a terrible infection. The goal of this experiment is to have participants take Finasteride, a medication that blocks testosterone production, for 2 weeks and evaluate the following: * Blood levels of testosterone * Amount of bacteria on the skin. Participants will: * Be assigned to take Finasteride, or a placebo (a look-alike pill with no active medicine) once daily, for 2 weeks * Have a small sample of their blood collected and their skin swabbed with a Q-tip to determine Testosterone levels and bacteria on the skin * Blood draw and skin testing will take place before starting Finasteride or the placebo (day 0) and at the end of the experiment (day 14).
Conditions
- Dihydrotestosterone
- Periprosthetic Joint Infection (PJI)
- Cutibacterium Acnes
Interventions
Finasteride 5 mgDrug
Patients randomized to the experimental group will receive oral Finasteride 1 mg, taken daily, for two weeks
Placebo ControlDrug
Patients randomized to the placebo group will receive one pill containing no active medicine, taken daily, for two weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cutibacterium skin loadTime frame: Skin load will be assessed at day 0 and at the end of the study on day 14 of treatment or placebo.
- Serum Dihydrotestosterone (DHT) LevelTime frame: levels will be assessed at baseline and after 14 consecutive days of treatment or placebo.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UW Medical Center - Montlake
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.